Analysts Offer Insights on Healthcare Companies: Teleflex (TFX) and MBX Biosciences, Inc. (MBX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teleflex (TFX) and MBX Biosciences, Inc. (MBX).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Teleflex (TFX)
In a report issued on April 22, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Teleflex, with a price target of $135.00. The company’s shares closed last Thursday at $136.65, close to its 52-week low of $128.55.
According to TipRanks.com, Chadha is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Teleflex with a $135.75 average price target, implying a -2.0% downside from current levels. In a report issued on April 13, Bank of America Securities also upgraded the stock to Hold with a $135.00 price target.
See the top stocks recommended by analysts >>
MBX Biosciences, Inc. (MBX)
In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on MBX Biosciences, Inc.. The company’s shares closed last Thursday at $33.39.
According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of
MBX Biosciences, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $69.20.
Read More on TFX:
